The effect of shot blocker and vibration on the intensity of pain and bruising caused by enoxaparin injection heart patient

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20240430061604N3

Enrollment

Registered

2024-07-05

Start date

2024-03-16

Completion date

Unknown

Last updated

2024-07-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ischemic Heart patients. Chronic ischemic heart disease, unspecified

Interventions

Intervention 1: A shot blocker will be used in one group. The nurse will keep the shot blocker in place for 5 seconds before the injection, and the injection needle will not release the pressure. Peop

Eligibility

Sex/Gender

All

Age

40 Years to 65 Years

Inclusion criteria

Inclusion criteria: Age 40 to 65 years old No neuromuscular disease No skin disease, known coagulation disorder, no type 1 or type 2 diabetes treated with insulin No swelling, wound, scratch and redness in the injection area Body mass index between 18.5 30 If there is a venous sampling, it will not interfere with the time of enoxaparin injection and will not affect the pain level caused by the injection Will not receive another drug through subcutaneous injection

Exclusion criteria

Exclusion criteria: Death of the patient Patient discharge before 48 hours

Design outcomes

Primary

Measure	Time frame
Severity of pain and bruising. Timepoint: Intensity of pain caused by enoxaparin injection in cardiac patients of shot blocker, vibration and control groups at the time of injection. Method of measurement: Visual scale for measuring pain intensity.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMaryam Mokhtari seghaleh

Birjand University of Medical Sciences

maryammoktari3ghale@gmail.com+98 56 3162 7300

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026